Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 16, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary Share ADR interests for specific individuals following the reinvestment of the dividend paid on January 4, 2007. The transaction price was $54.67 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Key Facts for Investors
- Transaction Type: Reinvestment of dividends into Ordinary Share ADRs.
- Transaction Date: February 16, 2007.
- Price per ADR: $54.67.
- Dividend Reference: Dividend paid to shareholders on January 4, 2007.
- Participants: Dr. JP Garnier (604.15 ADRs), Mr. D Phelan (129.46 ADRs), and Mr. D Stout (62.70 ADRs).